Search Results

LSL Pharma Group Inc. announced that it has entered into an exclusive agreement with Fera Pharmaceuticals, LLC, a U.S. specialty pharmaceutical company, to provide Erythromycin ophthalmic ointment USP for the treatment of newborns in U.S. hospitals.

Fera is pleased to announce that FDA has granted Orphan Drug Designation for Phospholine Iodide as a treatment for Stargardt disease.

Nicox SA, an international ophthalmology company, and Fera Pharmaceuticals, a privately-held, U.S. specialty pharmaceutical company, announced that the United States Food and Drug Administration has granted Orphan Drug Designation for naproxcinod for the treatment of sickle cell disease, which affects an estimated 100,000 Americans.

Fera is pleased to announce that, in addition to its already marketed 100-count bottle package size, it has now launched a 100-count unit dose blister package as well.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.

The US Food and Drug Administration (FDA) has approved Fera’s New Drug Application (NDA) for Avaclyr™ (acyclovir ophthalmic ointment) 3% for the treatment of herpetic keratitis.